Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:ATCCode |
L02BG04
|
| gptkbp:CASNumber |
gptkb:65807-02-5
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C17H11N5
|
| https://www.w3.org/2000/01/rdf-schema#label |
65807-02-5
|
| gptkbp:IUPACName |
gptkb:4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
|
| gptkbp:molecularWeight |
285.31 g/mol
|
| gptkbp:name |
gptkb:Letrozole
|
| gptkbp:synonym |
gptkb:Femara
|
| gptkbp:usedAs |
aromatase inhibitor
|
| gptkbp:usedFor |
treatment of hormone receptor positive breast cancer
|
| gptkbp:bfsParent |
gptkb:Zoladex
|
| gptkbp:bfsLayer |
7
|